Alectinib, Brigatinib, and Lorlatinib are the preferred options but, in the absence of head-to-head comparisons, the optimal choice for first-line therapy in ALK-rearranged lung cancer remains unclear [15]. The gene discussed is ALK; the disease is lung cancer.